Table 1

Baseline characteristics of rituximab treated RA patients

Demographics
 Age, years55±12
 Female, n (%)42 (86)
Disease characteristics
 RA duration, years9.8 (4.1–18.5)
 DAS28 score5.7±1.3
 ESR, mm/h23 (10–46)
 CRP, mg/l15 (3–30)
 IgM RF positive, %34 (71)
 ACPA positive, %36 (75)
 Erosive disease, %35 (73)
Medication
 Previous biologicals, n2 (1–2)
 >1 biological in history, n (%)25 (52)
 Previous DMARDS, n3.9±1.4
 Current prednisolone use, n (%)35 (73)
 Prednisolone dosage, mg/day7.5 (0–10)
 Current MTX use, n (%)30 (63)
 MTX dosage, mg/week13.8 (0–25)
 Current SSZ use, n (%)9 (19)
 Current HCQ use, n (%)10 (21)
Other characteristics
 Body mass index, kg/m226.9±6.1
 Smoking, n (%)26 (57)
 Diabetes mellitus, n (%)6 (12)
 Thyroid disease, n (%)4 (8)
 Lipid lowering drugs, n (%)7 (14)
  • Continuous variables are presented as mean with SD or median with IQR when appropriate.

  • ACPA, anticyclic citrullinated protein; CRP, C reactive protein; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; IgM, immunoglobulin M; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SSZ, sulphasalazyne.